A new standard for treating limited-stage small cell lung cancer – Sarah Cannon Research Institute

Sarah Cannon Research Institute shared on LinkedIn:

“Dr. David R. Spigel recently shared research on durvalumab and how it has set a new standard for treating limited-stage small cell lung cancer, offering improved survival rates for patients. Explore the impactful findings from the ADRIATIC trial here: [ADRIATIC Trial: A New Beginning For The Treatment of LS-SCLC].”

Source: Sarah Cannon Research Institute/LinkedIn